ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 570,62
-0,81%
Dow Jones
40 211,72
0,53%
DAX
18 473,67
-0,68%
Brent Oil
83,585
-0,90%
Bitcoin
62 609,29
-3,46%
Registration Strip Icon for default Inscrivez-vous gratuitement pour obtenir des cotations en temps réel, des graphiques interactifs, un flux d'options en direct et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Intellia Therapeutics Inc (NTLA)

  7. Intellia Therapeutics Inc (NTLA) Actualités

NTLA

Intellia Therapeutics (NTLA)

Intellia Therapeutics Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:NTLA
DateHeureSourceTitreSymboleSociété
12/10/201823h31Edgar (US Regulatory)Automatic Shelf Registration Statement of Securities of Well-known Seasoned Issuers (s-3asr)NASDAQ:NTLAIntellia Therapeutics Inc
24/09/201814h30GlobeNewswire Inc.Intellia Therapeutics to Present at October Healthcare Investor ConferencesNASDAQ:NTLAIntellia Therapeutics Inc
10/09/201822h30GlobeNewswire Inc.CRISPR Therapeutics, Intellia Therapeutics and Caribou Biosciences Provide Update on U.S Federal Circuit Decision Upholding t...NASDAQ:NTLAIntellia Therapeutics Inc
27/08/201814h00GlobeNewswire Inc.Intellia Therapeutics to Present at September Healthcare Investor ConferencesNASDAQ:NTLAIntellia Therapeutics Inc
23/08/201822h01GlobeNewswire Inc.Intellia Therapeutics Presents Progress in Lead In Vivo Program at Cold Spring Harbor Laboratory’s Fourth Meeting on Genome...NASDAQ:NTLAIntellia Therapeutics Inc
23/08/201814h30GlobeNewswire Inc.Intellia Therapeutics to Host Educational Briefing Webinar on Interference Proceedings Relating to CRISPR/Cas9 Genome Editing...NASDAQ:NTLAIntellia Therapeutics Inc
10/08/201822h45Edgar (US Regulatory)Initial Statement of Beneficial Ownership (3)NASDAQ:NTLAIntellia Therapeutics Inc
01/08/201813h48Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:NTLAIntellia Therapeutics Inc
01/08/201813h31Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:NTLAIntellia Therapeutics Inc
01/08/201813h30GlobeNewswire Inc.Intellia Therapeutics Announces Second Quarter 2018 Financial ResultsNASDAQ:NTLAIntellia Therapeutics Inc
18/07/201814h41Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:NTLAIntellia Therapeutics Inc
19/06/201815h05GlobeNewswire Inc.CRISPR Therapeutics, Intellia Therapeutics and Caribou Biosciences Announce Grant of U.S. Patent for CRISPR/Cas9 Genome Editi...NASDAQ:NTLAIntellia Therapeutics Inc
17/05/201813h30GlobeNewswire Inc.Intellia Therapeutics Announces WT1 as Its First Cell Therapy Target, Following Presentation of Early Data at the American So...NASDAQ:NTLAIntellia Therapeutics Inc
14/05/201813h30GlobeNewswire Inc.New Scientific Advisors Focused on Cell Therapy in Immuno-Oncology and Autoimmunity Join Intellia TherapeuticsNASDAQ:NTLAIntellia Therapeutics Inc
02/05/201815h09GlobeNewswire Inc.Intellia Therapeutics Announces First Quarter 2018 Financial ResultsNASDAQ:NTLAIntellia Therapeutics Inc
01/05/201813h16Edgar (US Regulatory)Amended Annual Report (10-k/a)NASDAQ:NTLAIntellia Therapeutics Inc
23/04/201815h29GlobeNewswire Inc.UPDATE -- Intellia Therapeutics Announces In Vivo and Ex Vivo Data Presentations at the American Society of Gene and Cell The...NASDAQ:NTLAIntellia Therapeutics Inc
23/04/201814h30GlobeNewswire Inc.Intellia Therapeutics Announces In Vivo and Ex Vivo Data Presentations at the American Society of Gene and Cell Therapy 21st ...NASDAQ:NTLAIntellia Therapeutics Inc
17/04/201813h31Edgar (US Regulatory)Proxy Statement (definitive) (def 14a)NASDAQ:NTLAIntellia Therapeutics Inc
23/03/201822h30Edgar (US Regulatory)Amended Statement of Beneficial Ownership (sc 13d/a)NASDAQ:NTLAIntellia Therapeutics Inc
14/03/201813h06Edgar (US Regulatory)Annual Report (10-k)NASDAQ:NTLAIntellia Therapeutics Inc
14/03/201812h30GlobeNewswire Inc.Intellia Therapeutics Announces Fourth Quarter and Full Year 2017 Financial ResultsNASDAQ:NTLAIntellia Therapeutics Inc
28/02/201822h30GlobeNewswire Inc.Intellia Therapeutics to Present at March Healthcare Investor ConferencesNASDAQ:NTLAIntellia Therapeutics Inc
27/02/201815h28GlobeNewswire Inc.Intellia Therapeutics Announces Publication in Cell Reports of Preclinical Data Demonstrating Effective CRISPR/Cas9 Genome Ed...NASDAQ:NTLAIntellia Therapeutics Inc
13/02/201815h55Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:NTLAIntellia Therapeutics Inc
31/01/201822h30GlobeNewswire Inc.Intellia Therapeutics to Present at February Healthcare Investor ConferencesNASDAQ:NTLAIntellia Therapeutics Inc
18/12/201713h30GlobeNewswire Inc.Intellia Therapeutics Names John Leonard, M.D., President and Chief Executive OfficerNASDAQ:NTLAIntellia Therapeutics Inc
11/12/201713h00GlobeNewswire Inc.Intellia Therapeutics Announces New, Robust Genome Editing Data for Sickle Cell Disease at the American Society of Hematology...NASDAQ:NTLAIntellia Therapeutics Inc
03/11/201711h05Edgar (US Regulatory)Prospectus Filed Pursuant to Rule 424(b)(5) (424b5)NASDAQ:NTLAIntellia Therapeutics Inc
02/11/201721h30GlobeNewswire Inc.Intellia Therapeutics to Present at November Healthcare Investor ConferencesNASDAQ:NTLAIntellia Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:NTLA

Dernières Valeurs Consultées

NASDAQ
SPCMU
Sound Point Acquisition ...
USOTC
RGWLS
RSE Archive (GM)
LSE
0QZU
Vertex Pharmaceuticals
LSE
0CZ7
Stademos Hotels
LSE
0EO8
Helgeland Sparebank
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés